共 50 条
- [1] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 56 WEEKS FROM A PHASE 2A, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDYANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 201 - 201Deodhar, A.Gottlieb, A. B.Boehricke, W-H.Dong, B.Wang, Y.Zhuang, Y.Barchuk, W.Xu, X. L.Hsia, E.
- [2] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB, AN ANTI-IL23 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 24 WEEKS: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDYANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 142 - 143Deodhar, A.Gottlieb, A.Boehncke, W. -H.Dong, B.Wang, Y.Barchuk, W.Xu, X. L.Hsia, E.
- [3] Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled StudyARTHRITIS & RHEUMATOLOGY, 2016, 68Deodhar, Atul A.Gottlieb, Alice B.Boehncke, Wolf-HenningDong, BinWang, YuhuaBarchuk, WilliamXu, XieHsia, Elizabeth C.
- [4] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyLANCET, 2018, 391 (10136): : 2213 - 2224Deodhar, AtulGottlieb, Alice B.Boehncke, Wolf-HenningDong, BinWang, YuhuaZhuang, YanliBarchuk, WilliamXu, Xie L.Hsia, Elizabeth C.
- [5] Efficacy and safety of guselkumab, an anti-IL23 Monoclonal antibody, in patients with active psoriatic arthritis: A phase 2a, randomized, double-blind, placebo-controlled studyJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB111 - AB111Gottlieb, AliceDeodhar, AtulBoehncke, Wolf-HenningDong, BinWang, YuhuaBarchuk, WilliamHsia, Elizabeth
- [6] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 56 WEEKSACTA DERMATO-VENEREOLOGICA, 2018, 98 : 48 - 49Boehncke, Wolf HenningGottlieb, AliceDeodhar, AtulDong, BinWang, YuhuaZhuang, YanliBarchuk, WilliamXu, Xie L.Hsia, Elizabeth
- [7] Efficacy and safety of Guselkumab through 2 years: Results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritisEXPERIMENTAL DERMATOLOGY, 2021, 30 : 38 - 38McInnes, I.Rahman, P.Gottlieb, A.Hsia, E.Kollmeier, A.Xu, X.Sheng, S.Jiang, Y.Shawi, M.Chakravarty, S.van der Heijde, D.Mease, P.
- [8] Efficacy of ixekizumab in patients with psoriatic arthritis: Results of a phase 3 randomized, double-blind, active- and placebo-controlled studyJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248Mease, Philipvan der Heijde, DesireeRitchlin, ChristopherCuchacovich, RachelShuler, CatherineLin, Chen-YenVangerow, HaraldSamanta, SuvajitLee, ChinGladman, Dafna
- [9] Safety of efalizumab in patients with psoriatic arthritis: Results of a phase II, randomized, double-blind, placebo-controlled studyJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156Papp, KMease, PGarovoy, MZhang, D
- [10] EFFICACY AND SAFETY OF GUSELKUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE AXIAL PSORIATIC ARTHRITIS: STUDY DESIGN OF A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1574 - 1575Gladman, D. D.Mease, P. J.Bird, P.Soriano, E.Chakravarty, S. D.Shawi, M.Xu, S.Quinn, S.Gong, C.Leibowitz, E.Tam, L. S.Helliwell, P.Kavanaugh, A.Deodhar, A.Ostergaard, M.Baraliakos, X.